A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 14
- 主要终点
- Number of Participants Without a Device Related Adverse Events Within 1 Month of the Study Procedure.
研究概览
简要总结
This study was a prospective observational study examined the safety of the TriVascular AAA Stent-Graft System in the elective treatment of patients with abdominal aortic aneurysms. Specifically, the study will evaluate the safety of the TriVascualr AAA Stent-Graft System, evaluate the ability to deliver the Tri-Vascular AAA Stent-Graft System to the desired location within the aorta, and evaluate the ability of the TriVascular AAA Stent-Graft to exclude the abdominal aortic aneurysm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or infertile female
- •Have signed an informed consent form.
- •Are considered an appropriate candidate for open surgical repair of an abdominal aortic aneurysm.
- •at least one of the following: Abdominal aortic aneurysm >= 4.5 cm in diameter; aneurysm has increased in size by 0.5cm in last 6 months; maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent normal aortic segment; saccular aneurysm larger than 3 cm.
- •Have patent iliac or femoral arteries that allow endovascular access to the aneurysmal site with a 17F Delivery Catheter.
排除标准
- •A dissecting, acutely ruptured, or leaking aneurysm, or an acute vascular injury due to trauma.
- •A need for emergent surgery.
- •contraindication to undergoing angiography.
- •A Thoracic aortic aneurysm that requires treatment.
- •Presence of thrombus or atheroma in proximal aortic neck covering > 50% of the endoluminal surface.
- •Presence of diffuse atherosclerotic disease in either common iliac artery that reduces the iliac artery diameter to <7mm.
- •Congenital abnormalities in which the placement of the stent-graft will cause occlusion of major arterial flow. Such abnormalities should be evaluated(e.g. angiography or CT) prior to treatment.
- •Unstable angina
- •Morbid obesity or other clinical conditions that severely inhibit x-ray visualization of the aorta.
- •Connective tissue disease (e.g., Marfan's or Ehlers-Danlos syndrome.)
- •Hypercoagulable state.
- •Contraindication for anticoagulation.
- •Acute renal failure.
- •Active systemic infection.
- •less than 18 years of age.
- •Life expectancy less than 1 year.
- •Current, or anticipated participation within 1 year, in another research study involving an investigational device or new drug (with the exception of participation in the Lifeline Registry of Endovascular Therapy).
- •Other medical, social, or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
结局指标
主要结局
Number of Participants Without a Device Related Adverse Events Within 1 Month of the Study Procedure.
时间窗: 1 month
Device related adverse events included, but were not limited to: Stent Graft Migration, Vessel dissection or perforation, stent graft occlusion, branch vessel occlusion, aneurysm rupture.
Number of Participants Without a Type I, III, and/or IV Endoleak at 1 Month Follow-up Identified by Computed Tomography (CT).
时间窗: 1 month
A Type I endoleak is a persistent perigraft channel of blood flow that develops due to inadequate or ineffective seal at the graft ends (attachment zones). A Type III endoleak occurs in the midgraft region due to leakage through a defect in the graft fabric or between the segments of a multisegmental graft. A Type IV endoleak is seen on completion of angiography or subsequent contrast studies as any blush of contrast that is presumed to emanate from blood diffusion across the porous graft fabric or through small holes in the graft cause by sutures or stent struts.
次要结局
- Number of Participants Who Achieve Technical Success of the Stent Graft System.(Post procedure)